|

Neurokinin-1 receptor antagonist Clinical Trials

1 actively recruiting trial across 1 location

Also known as: NK-1 receptor antagonist

Pipeline

Phase 2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC1

Indications

  • Carcinoma, Non-Small-Cell Lung1
  • Lung Cancer1
  • Cancer1

Lexington, Kentucky1 trial

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

University of Kentucky Chandler Medical Center ( Site 0019)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.